Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Vertex acquires diabetes stem cell company

by Ryan Cross
September 6, 2019 | A version of this story appeared in Volume 97, Issue 35

 

Vertex Pharmaceuticals is moving beyond its cystic fibrosis small-molecule franchise. The company is purchasing the Cambridge, Massachusetts–based start-up Semma Therapeutics, which is designing stem cell therapies for type 1 diabetes, for $950 million in cash. Semma has a method for turning stem cells into insulin-secreting β cells, which it licensed from Harvard University’s Douglas Melton. The company plans to start clinical trials of its β cell injections next year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.